Yes-Associated Protein May Hold Prognostic Value in Cutaneous Melanoma

Source: AJMC, April 2024

A retrospective study analyzing tissue assays from patients with cutaneous melanoma demonstrated the promise of yes-associated protein (YAP) as a predictive biomarker for melanoma prognosis.

Yes-associated protein (YAP) may be a valuable biomarker in the prognosis of cutaneous melanoma, and interventions that target YAP inhibition could provide benefits for affected patients, according to a recent study published in Laboratory Investigation.

Cutaneous melanoma is not as common as other forms of skin cancer; however, it constitutes one of the more fatal skin cancer diagnoses. Patient outcomes in this disease can be influenced by a myriad of factors such as the thickness of the tumor, lymphatic invasion, microscopic satellites, regression, and more. Due to the plethora and variety of features affecting patient prognosis, finding ways to predict disease behavior that can inform therapeutic approaches constitute an urgent clinical need in cutaneous melanoma.
READ THE ORIGINAL FULL ARTICLE